DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cathflo Activase (Alteplase) - Summary

 

-- advertisement --

SUMMARY

Cathflo® Activase® (Alteplase) is a tissue plasminogen activator (t-PA) produced by recombinant DNA technology. It is a sterile, purified glycoprotein of 527 amino acids. It is synthesized using the complementary DNA (cDNA) for natural human tissue-type plasminogen activator (t-PA) obtained from an established human cell line. The manufacturing process involves secretion of the enzyme Alteplase into the culture medium by an established mammalian cell line (Chinese hamster ovary cells) into which the cDNA for Alteplase has been genetically inserted. Fermentation is carried out in a nutrient medium containing the antibiotic gentamicin sulfate, 100 mg/L. The presence of the antibiotic is not detectable in the final product.

Cathflo® Activase® (Alteplase) is indicated for the restoration of function to central venous access devices as assessed by the ability to withdraw blood.

NEWS HIGHLIGHTS RELATED TO CATHFLO ACTIVASE

Media Articles Related to Cathflo Activase (Alteplase)

Landmark Study Shows Thrombolytic Treatment Improves Outcomes In Stroke When Given Up To 4.5 Hours After Symptom Onset
Source: Stroke News From Medical News Today [2008.10.02]

Recent Research Shows Significant Benefits In Acute Ischaemic Stroke With Actilyse(R) Beyond Currently Approved Three Hour Treatment Window
Source: Stroke News From Medical News Today [2008.09.25]

more>>

Published Studies Related to Cathflo Activase (Alteplase)

Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial. [2007.06]

Short and long alteplase dwells in dysfunctional hemodialysis catheters. [2005.04]

Comparison of rapidity of coronary recanalization in men with tenecteplase versus alteplase in acute myocardial infarction. [2004.06.15]

Effect of activated protein C on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction treated with alteplase: comparison with unfractionated heparin. [2003.10.15]

One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction. [2003.07]

more>>

Clinical Trials Related to Cathflo Activase (Alteplase)

Cathflo Activase Pediatric Study [Completed]

Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants [Recruiting]

Phase II Clinical Trial on Treatment of Intraventricular Hemorrhage [Recruiting]

Alteplase for Blood Flow Restoration in Hemodialysis Catheters [Recruiting]

Ateplase for Percutaneous Treatment of Loculated Abdominopelvic Abscesses [Recruiting]

more>>

Page last updated: 2008-10-02

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008